In this study, we examine the role of Mcl-1 in the resistance of GBM to TRAIL and identify R-roscovitine as a potential candidate drug that targets Mcl-1 to enhance the therapeutic effects of TRAIL in the treatment of TRAIL resistant GBM cells and in a 3D tumour model. This evidence concerns the gene MCL1 and neoplasm.